Monday, January 6, 1997
ImmuLogic Pharmaceutical Corp. took two steps forward in its
relations with the FDA, and two steps back in the timeline for development of
its Allervax Cat peptide for cat allergy.
Based on its Dec. 19 meeting with the agency, the company last week
said that it will begin a new study of Allervax Cat in the second quarter of 1997, to be
followed by a larger study, prior to a PLA filing. The first trial probably will take
about six months, though it might last longer if IMUL decides to look at long-term effects
of its compound in patients with chronic asthma. Those patients will be among a variety of
patients the company plans to enroll in the new trial, according to Acting President and
CEO Joseph Marr.